Medlab Clinical Ltd (ASX.MDC)

NanaBis™

A differentiated, late-stage drug candidate addressing unmanageable cancer pain

DISCLAIMER

This presentation has been prepared by Medlab Clinical Limited ABN 51 169 149 071 ("Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out
in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor their respective related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks.
The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of their respective directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects.
The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

INVESTMENT HIGHLIGHTS

- Medlab Portfolio of novel drug candidates – using known active ingredients - optimised by NanoCelle® platform
- Lead candidate NanaBis™ highly purified blend of CBD:THC (medical cannabis) for the treatment of cancer-induced pain
- Phase I/IIa study met primary and secondary endpoints –in bone cancer patients achieved a 40% reduction in pain and reduced dosage of opioids
- Clinical results replicated in real-world observation study, demonstrating 59% improvement in pain scores
- Generating proof of concept, prescribers and early revenue and increased uptake under Australian Special Access Scheme
- Targeting a global market opportunity, with a US FDA regulatory approved drug and early mover advantage
- Near-term milestones as we advance towards global Phase III study and Investigational New Drug (IND) filing


ABOUT NANABIS™

WHY NANABIS™?

Scientifically optimised to perform better

- 1 to 1 ratio THC and CBD
- Optimised by the NanoCelle® drug delivery platform for buccal in submicron doses in an easy and convenient spray
- High bioavailability, smaller doses and fast absorption into the bloodstream enhances performance and efficacy
- Highly purified, standardised blend ensuring pharmaceutical grade quality: GMP manufacturing and CMC (Chemistry, Manufacturing & Control) standards met



A NON-OPIOID ANALGESIC TO TREAT BONE PAIN

Up to 75% of patients with bone metastasis endure crippling bone pain…

- Opioids or opioid derivatives remain the main method of treatment of cancer-related pain
- Despite the known side-effects of opioids, there's been little advancement in the management of cancer pain
- Extended patient life increases the burden of pain
- Abuse and toxicity profiles underpin a need for opioid alternatives
- Each year in the US, more than 2 million people abuse opioids. In 2016, an estimated 197,970 US hospital visits occurred for opioid-related poisonings

WHY IS NANABIS™ IMPORTANT?

EMA STEPWISE
PAIN GUIDELINES

PAIN SCALE

Mixed Opioids & Adjuvants — 10

Low Dose Opioids & Adjuvants — 5

NSAID & Other Non-Opioid Medications — 0

NanaBis™ Therapeutic Entry Point

64% of all bone cancer patients are currently not helped by existing pain therapy

- NanaBis™ provides a viable alternative that can delay or alleviate the need to use opioids for pain management
- Effective and safe at the lower end of the pain scale – and used before progression to opiods
- Efficacious in patients with “unmanageable pain” that is not being controlled by opioids and other pain medication

medlab


TRIALS PATHWAY

NANABIS™ CLINICAL EXPERIENCE

Primary & Secondary endpoints met in Phase I/II study

- 30 advanced cancer pain patients, single ascending dose / multiple ascending dose
- Patient subset of breast or prostate cancers with bone metastasis had 40% improvement in pain scores from baseline
- Improvements in Quality of Life measures (emotional functioning and insomnia)
- MME (morphine in milligrams equivalent) significantly reduced - quantifiable measure of efficacy
- Maximum concentration in serum to be 54 minutes
- Results released in March 2020

ROYAL NORTH SHORE HOSPITAL

medlab

REAL WORLD DATA REPLICATES CLINICAL DATA

12 month observational (OBS) underway,
Data released every quarter

556 of 2000

Australian patients recruited (27.8%)

- Of which 15% in cancer-related pain, 85% in non-cancer-related pain
- Median averages = dosage 4 sprays per day corresponding to a 59.5% reported reduction in pain (unadjusted)
- Gender distribution = 58% female, 42% male across ages 20 – 80+

Real-world data

could expedite path to market

- Observational study is designed to provide real world evidence (RWE)
- Initiated following discussions with the US FDA regarding pathway to regulatory approval
- Strong body of RWE could reduce the total number of patients required to be observed in clinical trials

59% improvement in pain scores

Consistent with Phase I/II study

medlab

NANABIS™ NEXT MAJOR STEPS

Our progress validates our product, reduces the risk, increases commercial opportunities, and sets us apart as a world class offering.

Multiple milestones, creating news flow.



US FDA IND

US FDA IND filing
US FDA IND acceptance
Additional patents
Phase III trial preparations
Obs study quarterly progress report
Peer-review publication of Phase I/II trial

Phase III trial initiation:

US DEA Approval
UK MHRA / Home Office Approval
Clinical sites contracted
NanaBis™ to US & UK > first patient in, study sites underway
Obs study quarterly progress report

Phase III Completion

Enrolment complete
Phase III interim readout
Phase II final report
Obs study quarterly progress reports

US FDA Drug Filing

Phase III Final Report
Phase III peer review publications
Obs study completion
New Drug Application filing

ACCEPTANCE OF US FDA IND AN IMPORTANT VALIDATOR

- Investigational New Drug (IND) application to be filed with the US FDA in late 2020
- **IND acceptance is an important milestone – confirming merit of safety, quality and clinical data collected to date**
- Already seeing concessions from global regulators
- Pursuing a regulatory pathway extends the market opportunity and gives patients and prescribers confidence in quality, safety and efficacy



MARKET OPPORTUNITY

NANABIS™ COMPETITIVE POSITIONING

Currently 13 Trials on clinicaltrials.gov with “Cancer Pain” and “Cannabis”

- 7 are for Sativex completed or terminated
- 4 of the balance “terminated or withdrawn”
- 1 is Aurora with a capsul – Interventional
- Tetra BioPharma – not yet recruiting & little information

NIH U.S. National Library of Medicine
ClinicalTrials.gov



medlab

NANABIS™ — MARKET OPPORTUNITY WITH SIGNIFICANT GLOBAL POTENTIAL



IMMEDIATE REGULATORY TARGET

Cancer Bone Pain

$1.22B Global market (2019) with CAGR of 5.4%

Cancer Bone Pain (primarily in Breast, Prostate and Lung) About 700,000 new patients (annually) in US, AU and Canada

FUTURE TARGETS

Cancer Pain

$5.28B Global market opportunity (2017)

CAGR 4.5%, estimated to be $7.54B (2025)

Chronic Pain

$69.3B Global market opportunity (2017)

CAGR 6.4%, estimated to be $151.7B (2030)

INCREASING USE UNDER SPECIAL ACCESS SCHEME

Product sold under Special Access Scheme provides a strong proof of concept and early revenue




SUMMARY

NANABIS™ VALUE CREATION

Delivery of NanaBis™ will be company making event with global opportunity.



Delivery tech

NanaBis™ as a fast acting, non-opioid alternative for effective pain management

Delivered SAD/MAD (Phase I/II) study

Commenced Obs Study

Transferred production to TasAlk

Obs study consistent with clinical trials outcomes

US IND Filing expected

In market sales grow

Poised for P3; robust and clear drug pathway in US; EU and Australia

Over 300 AU doctors utilizing the drug via compassionate programs

NANABIS™ PART OF A BROADER MEDLAB R&D PORTFOLIO

Multiple options for partnering or in-house development

NAME	INDICATION	PRE CLIN	SAFETY	P1	P2B	P3	COLLABORATORS
Cannabis/platform							
NanaBis™	Cancer Pain (Bone Met)					Underway	AGILEX BIOLABS, TASMANIAN ALKALOIDS, Nitto Avecia, THE UNIVERSITY OF SYDNEY
NanaBidial™	CINV						AGILEX BIOLABS, scientia
NanoCBD™ (In designs)	Anxiety						Nitto Avecia
NanoCelle® Platform							
NanoStat™	Cholesterol Lowering						zentech
Lidocaine	Pain						
Fexofenadine	Allergy						
Chloroquine (In designs)	Anti-Malaria/Covid 19						
Metabolomic							
NRGBiotic™	Depression					Awaiting Results	THE UNIVERSITY OF QUEENSLAND AUSTRALIA, QUT Queensland University of Technology
Mesothelioma	Large Bowel Cancer						

medlab

SUMMARY

NanaBis™ 2020 opportunity – a potential company making event

- Large unmet need in pain management dominated by opioids
- Material trials success, reinforced by ongoing collection of real-world evidence
- Leading competitive position in “FDA pathway” strategy
- Delivering strong in market results today
- Validates the NanoCelle® platform

medlab


APPENDIX

COMPANY SNAPSHOT (ASX LISTED MDC)

NUMBERS SNAPSHOT

LISTED 2015	$0.20
CURRENT PRICE	$0.17
MARKET CAP CIRCA	$48M
AV DAILY TURNOVER (2020)	425K

MAJOR SHAREHOLDERS:

SEAN HALL (DIRECTOR)	20.9%
FARJOY PTY LTD	11.0%
DREW TOWNSEND (DIRECTOR)	5.8%
MICHAEL HALL (DIRECTOR)	5.7%
UBS NOMINEES NOMINEES PTY LTD	2.7%
JP MORGAN NOMINEES AUSTRALIA PTY LTD	2.6%

Lead drug candidate is cannabis cancer bone pain

NanoCelle® Delivery has partnering potential




BOARD AND
MANAGEMENT

BOARD OF DIRECTORS

Dr Sean Hall

MD, MBA (Clin Pharm Mgt)
CEO & Managing Director

Michael Hall

B.Com, CPA Non-Executive
Chairperson

Drew Townsend

B.Com, CA, MAICD,
Non-Executive Director

Laurence McAllister

Non-Executive Director

EXECUTIVE AND MANAGEMENT TEAM

Prof Luis Vitetta

BSc (Hons), PhD, MD, GradDip Nutr/Environ Med, Grad Dip Integ Med
Director of Medical Research

Alan Dworkin

CA, ACSA, GAICD, Chief Financial Officer, Chief Operations Officer, Company Secretary

Ian Curtinsmith

Chief Information Officer

Dr Patrick Miller

Director of Pharmacovigilance & Regulatory Affairs

Tony Potter

BSc (Hons), Dip Management
GM Pharma, Commercialisation & Education

Dr Jeremy Henson

MBBS PhD BSc (Hons) Medical Affairs Director

Dr David Rutolo, Jr.,

PhD, JD, Director of Science

MEDICAL & SCIENTIFIC CONSULTING TEAM

Prof Stephen Clarke

MbBS MD PhD FRACP
FAChPM FAAHMS

Ass Prof Wojciech Chrzanowski

MSc, PhD, DSc

Dr Andrew Mclachlan

BPharm (Hons1 Medal), PhD,
FPS, FACP, McPA, MSHPA

Dr Mathew Bambling

PhD

Dr Esben Strodl

BS's (Hons), MPsucjClin, PhD

CONSULTANTS AND COMMERCIAL PARTNERS

Margot Rothwell

Commercialisation and Business Consultant - MBA (Clin Pharm Mgt), Executive Director at BioAdvantage PTY Ltd

Benjamin L. England

Regulatory Representation and Counsel - Founding Member/CEO Benjamin L England & Associates, LLC | FDAImports.com, LLC

ERA Consulting Group

Tasmanian Alkaloids

Manufacture and analytical

Agliex Biolabs Pty Ltd

Human Assay, pathology

Nitto Avecia

Analytical

Aphria. Inc

Biomass supplier

THANK YOU

HEAD OFFICE

Medlab Clinical
Units 5 & 6 11 Lord St, Botany
NSW 2019, Australia

P +61 2 8188 0311
E sean_hall@medlab.co
M +61 411 603 378

CALIFORNIA OFFICE (USA)

Medlab Clinical US, Inc
30021 Tomas
Suite 150
Rancho Santa Margarita,
CA 92679, USA

P +1 949 636-4123